Are there gender differences in anti-HIV drug efficacy?

©2012 Mary Ann Liebert, Inc., publishers

Women comprise nearly half of the HIV-infected population worldwide, but these 15.5 million women tend to be under-represented in clinical trials of anti-HIV drug therapies. The U.S. Food and Drug Administration (FDA) has created a database from 40 clinical studies to assess gender differences in the efficacy of antiretroviral treatments. The results of this study are presented in an article in AIDS Patient Care and STDs.

Guoxing Soon and coauthors from the FDA and University of Texas Southwestern Medical Center, Dallas, TX, found that women represented only about 20% of the subjects in randomized clinical trials submitted to the FDA between 2000 and 2008. The article "Meta-Analysis of Gender Differences in Efficacy Outcomes for HIV-Positive Subjects in Randomized Controlled Clinical Trials of Antiretroviral Therapy (2000-2008)" compares the effectiveness of anti- regimens reported for women versus men overall and among various subgroups.

The authors found no statistically or clinical significant differences between women and men in outcomes with regard to viral load after 48 weeks. However, they did report significant favoring males based on subgroup analyses.

"This is a critical area of research in terms of developing new HIV therapies," says Editor-in-Chief Jeffrey Laurence, MD, Director of the Laboratory for Research at Weill Medical College of Cornell University, New York, NY. "Mounting evidence indicates that metabolism of certain drugs varies in men vs. women, and side effects that interfere with adherence to these medications may also be manifest differently."

More information: http://www.liebertpub.com/apc

Related Stories

US approves new HIV drug

date May 21, 2011

The US Food and Drug Administration on Friday approved a new drug, Edurant, to fight HIV in combination with other antiretrovirals already on the market.

HIV drug maraviroc effective for drug-resistant patients

date Oct 01, 2008

As many as one quarter of HIV patients have drug resistance, limiting their treatment options and raising their risk for AIDS and death. Now, maraviroc, the first of a new class of HIV drugs called CCR5 receptor antagonists, ...

Recommended for you

Indiana HIV outbreak, hepatitis C epidemic sparks US alert

date Apr 24, 2015

Federal health officials helping to contain an HIV outbreak in Indiana state issued an alert to health departments across the U.S. on Friday, urging them to take steps to identify and track HIV and hepatitis C cases in an ...

Why are HIV survival rates lower in the Deep South than the rest of the US?

date Apr 22, 2015

The Deep South region has become the epicenter of the US HIV epidemic. Despite having only 28% of the total US population, nine states in the Deep South account for nearly 40% of national HIV diagnoses. This region has the highest HIV diagnosis rates and the highest number of people living with HIV of any ...

A bad buzz: Men with HIV need fewer drinks to feel effects

date Apr 20, 2015

Researchers at Yale and the VA Pittsburgh Healthcare System compared the number of drinks that men with HIV infection, versus those without it, needed to get a buzz. They found that HIV-infected men were more sensitive to ...

Research informs HIV treatment policy for inmates

date Apr 16, 2015

A national, five-year study of care for inmates with HIV brought strangers together, produced policy change in the Delaware Department of Corrections and documented the importance of good communication and ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.